CDMO

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report 2024: Increasing Demand for One-Stop-Shop CDMOs and Orphan Drug Discovery - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, CDMO, Growth, Patient, Knowledge, DSM-IV codes, Cancer, Commercial, Merck & Co., Oncology, Investment, Johnson & Johnson, Janssen, Drug development, API, Patent, Therapy, USD, Fine chemical

The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.

Key Points: 
  • The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.
  • A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.
  • As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes.
  • CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Deafness, CDMO, Obesity, Syndrome, Infertility, Entrepreneurship, Disease, Diabetes, Ciliopathy, Patient, CRL, DNA, Display resolution, Kidney disease, GMP, Tecmar, Therapy, Paratriathlon, BBS, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024
Health, Manufacturing, Health Technology, Clinical Trials, Other Manufacturing, Pharmaceutical, Biotechnology, CDMO, Growth, Capsule, Risk, Rheometer, Acquisition, FT4, Senior, Investment, Clinical trial, API, Korsch, Fine chemical

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Retrieved on: 
Monday, April 8, 2024
Max Planck Society, Attention, CDMO, Growth, MSA, Master service agreement, CGMP, Laboratory, Drug development, Administration, Pharmaceutical industry

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.

Key Points: 
  • Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.
  • Ayana COO Yanir Aldouby, commented, "After an extensive search, we are pleased to have selected Scinai Bioservices as our CDMO for our future projects.
  • We were particularly attracted to the team's experience in bio-pharmaceutical drug development and manufacturing for clinical trials while meeting stringent international regulatory requirements.
  • As Scinai is also in the business of biological drug development, we believe they understand our needs as a small biopharma company.

CDMO LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO

Retrieved on: 
Sunday, March 24, 2024
Titan, Failure, CDMO, Acceleration, News, Relevant, Bank statement, Interest, Debt-to-GDP ratio, Advertising, Security (finance)

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23144 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman

Retrieved on: 
Thursday, March 21, 2024
SAN, Bank statement, CDMO, Hagens Berman, Note, Sale, Person, Cryptocurrency

12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023.

Key Points: 
  • 12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023.
  • The company blamed the misreporting on its misclassification of certain notes as long term liabilities and its failures to record additional interest expenses payable to note holders.
  • The debt in question is $143.8 million of 1.250% exchangeable senior notes due 2026 (“2026 Notes”) that Avid privately placed with qualified institutional investors in Mar.
  • In addition, the indenture governing the 2026 Notes required Avid to remove the legend by Mar.

SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Retrieved on: 
Thursday, March 21, 2024
Bank statement, Block & Leviton, CDMO, Cryptocurrency

BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Avid Bioservices, Inc. (NASDAQ: CDMO) for potential securities law violations.

Key Points: 
  • BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Avid Bioservices, Inc. (NASDAQ: CDMO) for potential securities law violations.
  • Investors who have lost money in their Avid Bioservices, Inc. investment should contact the firm to learn more about how they might recover those losses.
  • Shares of Avid Bioservices, Inc. dropped more than 28% in intraday trading on March 7, 2024.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, SCTL, KNTE

Retrieved on: 
Wednesday, March 20, 2024
Fraud, Advertising, CDMO, Sale, Society, Security (finance)

If you are a Whole Earth shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Whole Earth shareholder, click here to learn more about your rights and options .
  • If you are a Societal CDMO shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

Retrieved on: 
Wednesday, March 20, 2024
DPT, CDMO, Growth, Chairperson, Wynnefield Capital, University, Laboratory, Head, Senior, Marketing, Syringe, Investment, Annual report, Retirement, Calendar, Corporate development, Fiscal, Management

CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.

Key Points: 
  • This conclusion was based on an expansive strategic review process, including outreach to and engagement with over 75 buyers, including both strategic buyers and financial sponsors.
  • “The Board of Directors appreciates all of the hard work put into the strategic review process by the Company and its advisors.
  • The Board looks forward to working with the management team to lead the Company’s execution on its strategic plan,” said Craig Barbarosh, Chairman of the Board.
  • With these investments, Lifecore believes it is positioned for substantial growth as its additional aseptic capacity becomes available.